The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
Breast Cancer (Test)
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
3
Carotuximab Plus Apalutamide Improves PFS in mCRPC
4
Dr Dhakal on the Investigation of Novel CAR T-Cell Therapy Approaches in Myeloma
5